Welcome to our dedicated page for Entrada Therapeutics news (Ticker: TRDA), a resource for investors and traders seeking the latest updates and insights on Entrada Therapeutics stock.
Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a new class of medicines known as Endosomal Escape Vehicle (EEV™)-therapeutics. Founded in 2016 by 5AM Ventures, Entrada aims to make previously inaccessible intracellular targets reachable, thereby opening new avenues for treating serious diseases.
Entrada Therapeutics is pioneering the delivery of a wide range of therapeutics to various organs and tissues, thereby improving the therapeutic index. The company's portfolio includes programs targeting neuromuscular diseases, immunological disorders, and metabolic conditions, amongst others.
One of the company's most promising candidates is ENTR-601-44, which is being developed to treat Duchenne muscular dystrophy (DMD), particularly in patients who are exon 44 skipping amenable. The ongoing Phase 1 clinical trial for ENTR-601-44 aims to evaluate the safety, tolerability, pharmacokinetics, and target engagement in healthy volunteers. This trial has already enrolled its first participants, with data anticipated in the second half of 2024.
Recent Achievements:In recent news, Entrada Therapeutics received authorization from the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) and the Research Ethics Committee (REC) to conduct its Phase 1 clinical trial of ENTR-601-44. Additionally, the company reported robust financial results for the third quarter of 2023, with significant cash reserves and collaboration revenue marking crucial steps in their growth trajectory.
Strategic Milestones:Entrada Therapeutics is well-positioned to continue its strategic initiatives through 2025, thanks to its strong financial footing and ongoing collaborations. The company has also recently appointed Nathan J. Dowden as President and Chief Operating Officer, further strengthening its executive team.
Beyond its lead program, Entrada's pipeline includes several other candidates aimed at treating various subtypes of DMD and myotonic dystrophy type 1 (DM1). These developments underscore Entrada's commitment to advancing its modular EEV platform to address a broad spectrum of unmet medical needs.
For more detailed and up-to-date information about Entrada Therapeutics, please visit their official website and follow them on LinkedIn.
Entrada Therapeutics (Nasdaq: TRDA) has announced a collaboration with the Myotonic Dystrophy Clinical Research Network (DMCRN) to support the END-DM1 study, which aims to understand disease progression in myotonic dystrophy type 1 (DM1). This non-interventional study will provide critical data for future clinical trials. Entrada's clinical candidate, ENTR-701, is being developed to potentially treat DM1, with new preclinical data indicating improved therapeutic effects in mouse models. The company plans to file an IND application for ENTR-701 in 2023.
Entrada Therapeutics (Nasdaq: TRDA) announced the appointment of Karla MacDonald as Chief Corporate Affairs Officer, effective immediately. Ms. MacDonald, previously the Vice President of Corporate Communications and Investor Relations, will report to Dipal Doshi, President and CEO. Her extensive experience in biopharmaceutical communications and stakeholder engagement supports Entrada's focus on developing Endosomal Escape Vehicle (EEV™) therapeutics, particularly for neuromuscular diseases like Duchenne muscular dystrophy. The company is transitioning into a clinical stage entity this year.
Entrada Therapeutics (Nasdaq: TRDA) announced its participation at the William Blair Biotech Focus Conference in New York on July 12-13, 2022. A fireside chat featuring Dipal Doshi and Natarajan Sethuraman will be available for viewing starting July 11, 2022, at 9:00 a.m. ET on the company’s website, with a 90-day replay. Entrada focuses on developing Endosomal Escape Vehicle (EEV™) therapeutics to target previously inaccessible intracellular sites, targeting diseases like Duchenne muscular dystrophy and myotonic dystrophy.
Entrada Therapeutics (Nasdaq: TRDA), a biopharmaceutical company focused on advancing Endosomal Escape Vehicle (EEV™) therapeutics, announced its participation in the Goldman Sachs Global Healthcare Conference. The event will feature a fireside chat with President and CEO Dipal Doshi on June 14, 2022, at 2:40 p.m. PT in Rancho Palos Verdes, CA. A live webcast will be available on the company’s website, with a replay accessible for 90 days afterward.
Entrada Therapeutics, Inc. (Nasdaq: TRDA) announced its second clinical candidate, ENTR-701, aimed at treating myotonic dystrophy type 1. The company is on track to submit an Investigational New Drug application for ENTR-601-44, targeting Duchenne muscular dystrophy, in Q4 2022. As of March 31, 2022, Entrada has $263.9 million in cash and equivalents, projecting sufficient funds to support operations into the second half of 2024. However, the first quarter of 2022 reported a net loss of $21.7 million, significantly higher than the $8.4 million loss in Q1 2021.
Entrada Therapeutics (Nasdaq: TRDA) has shared promising non-human primate data for its lead candidate, ENTR-601-44, indicating a durability of response for 12 weeks in treating Duchenne muscular dystrophy (DMD). The company also introduced ENTR-701, targeted at myotonic dystrophy type 1 (DM1). Both candidates are set for Investigational New Drug applications: ENTR-601-44 in Q4 2022 and ENTR-701 in 2023. These advancements reinforce Entrada's commitment to developing intracellular therapeutics with potential for transformative patient outcomes.
Entrada Therapeutics (Nasdaq: TRDA) announced that CEO Dipal Doshi will present virtually at the H.C. Wainwright Global Investment Conference from May 23-26, 2022. The presentation will be accessible starting May 23, 2022, at 7:00 a.m. ET on the company's website. A replay will be available for 90 days after the event.
Entrada focuses on Endosomal Escape Vehicle (EEV™) therapeutics to deliver medicines intracellularly, particularly for conditions like Duchenne muscular dystrophy and myotonic dystrophy.
Entrada Therapeutics (Nasdaq: TRDA) reported financial results for the fourth quarter and full year ending December 31, 2021. The company secured approximately $209 million from its IPO and held $291.1 million in cash as of year-end. Planned developments include submitting an IND application for ENTR-601-44 targeting Duchenne muscular dystrophy in the second half of 2022. R&D expenses rose to $12.4 million for Q4 2021, with a net loss of $18.4 million. G&A expenses also increased significantly, reflecting higher personnel and professional fees.
Entrada Therapeutics (Nasdaq: TRDA) will have its CEO, Dipal Doshi, participate in the Neuromuscular Panel at the Cowen 42nd Annual Health Care Conference on March 7, 2022, at 9:10 a.m. ET. The event aims to discuss the company’s innovative therapeutics, specifically its Endosomal Escape Vehicle (EEV™) technology. A live webcast will be available on Entrada’s website, with a replay accessible for 90 days post-event. The company focuses on developing treatments for neuromuscular diseases and has a robust portfolio targeting conditions like Duchenne muscular dystrophy.
Entrada Therapeutics (Nasdaq: TRDA) has appointed Jared Cohen, PhD, JD, as General Counsel, effective immediately. This move is a recognition of his significant contributions since joining the company, particularly in legal and compliance functions during recent financings. Dr. Cohen, who has nearly 20 years of experience in the healthcare sector, previously held leadership positions at several biopharmaceutical organizations. His appointment is expected to guide Entrada through its next phase of growth in developing its innovative Endosomal Escape Vehicle (EEV™) therapeutics.
FAQ
What is the current stock price of Entrada Therapeutics (TRDA)?
What is the market cap of Entrada Therapeutics (TRDA)?
What is Entrada Therapeutics' core business?
What is ENTR-601-44?
What recent milestones has Entrada Therapeutics achieved?
What is the aim of the ongoing clinical trial for ENTR-601-44?
Who founded Entrada Therapeutics?
What diseases does Entrada Therapeutics aim to treat?
How is Entrada Therapeutics funded?
Who is the current CEO of Entrada Therapeutics?
Where can I find more information about Entrada Therapeutics?
What is the significance of the EEV™ platform?
